Cargando…

Barriers to Hepatitis C Treatment in HIV co-infected Patients in the Era of New Direct-Acting Antiviral Therapy

BACKGROUND: Hepatitis C virus (HCV) infection disproportionately affects HIV-infected patients. Co-infected patients have worse prognoses than mono-infected patients. HCV treatment with new oral direct acting antiviral (DAA) therapy is effective in HIV/HCV co-infected patients with cure rates simila...

Descripción completa

Detalles Bibliográficos
Autores principales:	Deering, Caytlin, Coppock, Dagan, Boyle, Suzanne, Szep, Zsofia, Franks, Taneesa, Scott, Tiffany, Kesaris, Anna, Chou, Edgar, Lee, Dong Heun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2017
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631048/ http://dx.doi.org/10.1093/ofid/ofx163.1760

Ejemplares similares

2221. Active Substance Use Should Not Be a Contraindication for Hepatitis C Treatment in Hepatitis C and Human Immunodeficiency Virus Co-infected Patients
por: Zeineddine, Nabil, et al.
Publicado: (2018)

308. Slow Adoption of a Nurse-Driven Protocol for Universal Hepatitis C Virus Screening in a Hospital Emergency Department: Lessons Learned
por: Wasti, Zainab, et al.
Publicado: (2019)

2205. Mandatory Infectious Diseases or Hepatology Consult to Improve HCV Linkage to Care in the Inpatient Setting
por: Ingilizova, Marinela, et al.
Publicado: (2018)

2209. Discordance Between FibroSure and FibroScan Results in Hepatitis C and Human Immunodeficiency Virus Co-infected Patients Prior to Treatment for Hepatitis C Virus Infection
por: Tiyouh, Melissa, et al.
Publicado: (2018)

How Can We Do Better? Experience of Hepatitis C Testing for Baby Boomers (1945–1965) in Six Primary Care Clinics
por: Bluen, Benjamin, et al.
Publicado: (2017)

2899. Decreased Hepatitis C Virus-Associated Mortality in the US 2014–2017 After New Oral Direct-Acting Antiviral Era
por: Wasti, Zainab, et al.
Publicado: (2019)

Hepatitis C antibody screening and determinants of initial and duplicate screening in the baby boomer patients of six urban primary care clinics
por: Coppock, Dagan, et al.
Publicado: (2020)

2410. Clinical Outcomes Associated With Various Treatment Options for Infections Caused by Carbapenem-Resistant Enterobacteriaceae
por: Bandali, Aiman, et al.
Publicado: (2018)

Barriers to care for chronic hepatitis C in the direct-acting antiviral era: a single-centre experience
por: Nguyen, Peter, et al.
Publicado: (2017)

Increasing success and evolving barriers in the hepatitis C cascade of care during the direct acting antiviral era
por: Zuckerman, Autumn, et al.
Publicado: (2018)

Hepatitis C Screening and Treatment Program in Hungarian Prisons in the Era of Direct Acting Antiviral Agents
por: Werling, Klára, et al.
Publicado: (2022)

Polymicrobial bacteremia and Strongyloides hyperinfection syndrome: Vigilance in patients on corticosteroids
por: Boyle, Evan, et al.
Publicado: (2022)

Management of hepatitis C genotype 4 in the directly acting antivirals era
por: Hathorn, Emma, et al.
Publicado: (2016)

Hepatitis C virus infection in children in the era of direct-acting antiviral
por: Pawlowska, Malgorzata, et al.
Publicado: (2018)

Hepatic steatosis in HCV-infected persons in the direct-acting antiviral era
por: Stevenson, Heather L., et al.
Publicado: (2016)

Next Steps Toward Eradication of Hepatitis C in the Era of Direct Acting Antivirals
por: Hesamizadeh, Khashayar, et al.
Publicado: (2016)

Managing HIV/hepatitis C co-infection in the era of direct acting antivirals
por: Rockstroh, Jürgen K, et al.
Publicado: (2013)

Use of Ribavirin for Hepatitis C Treatment in the Modern Direct-acting Antiviral Era
por: Mathur, Poonam, et al.
Publicado: (2018)

Future of liver disease in the era of direct acting antivirals for the treatment of hepatitis C
por: Ponziani, Francesca Romana, et al.
Publicado: (2017)

Unmet needs of chronic hepatitis C in the era of direct-acting antiviral therapy
por: Huang, Chung-Feng, et al.
Publicado: (2020)

A Case of Invasive Pneumococcal Infection with Septic Shock and Rare Complications
por: Woytanowski, John R., et al.
Publicado: (2017)

Interferon-based combination treatment for chronic hepatitis C in the era of direct acting antivirals
por: Alexopoulou, Alexandra, et al.
Publicado: (2015)

Ribavirin revisited in the era of direct‐acting antiviral therapy for hepatitis C virus infection
por: Feld, Jordan J., et al.
Publicado: (2016)

Treatment of chronic hepatitis C-associated cryoglobulinemia vasculitis at the era of direct-acting antivirals
por: Comarmond, Cloé, et al.
Publicado: (2020)

Hepatitis C Virus in the Elderly in the Direct-Acting Antiviral Era: from Diagnosis to Cure
por: Mohammed Abdul, Mubeen Khan, et al.
Publicado: (2020)

Strategies for treating and managing chronic hepatitis C in children in the direct-acting antiviral era
por: Hong, Suk-Jin, et al.
Publicado: (2020)

Are There Still Difficult-to-Treat Patients with Chronic Hepatitis C in the Era of Direct-Acting Antivirals?
por: Pabjan, Paweł, et al.
Publicado: (2022)

Improved prognosis of hepatitis C‐related hepatocellular carcinoma in the era of direct‐acting antivirals
por: Fukumoto, Tsuyoshi, et al.
Publicado: (2022)

HIV/HCV Antiviral Drug Interactions in the Era of Direct-acting Antivirals
por: Rice, Donald P., et al.
Publicado: (2016)

Hepatitis C in the era of direct-acting antivirals: real-world costs of untreated chronic hepatitis C; a cross-sectional study
por: Kieran, Jennifer Ann, et al.
Publicado: (2015)

Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals
por: Gountas, Ilias, et al.
Publicado: (2019)

Expanding Treatment Access for Chronic Hepatitis C with Task-shifting in the Era of Direct-acting Antivirals
por: Yoo, Eric R., et al.
Publicado: (2017)

Hepatitis C virus pharmacogenomics in Latin American populations: implications in the era of direct-acting antivirals
por: Trinks, Julieta, et al.
Publicado: (2017)

Continuum of hepatitis C care cascade in prison and following release in the direct-acting antivirals era
por: Hariri, Sanam, et al.
Publicado: (2020)

Patterns of Hepatitis C-Related Inpatient Mortality in the United States in the Era of Direct-Acting Antivirals
por: Alzahrani, Mohammad S., et al.
Publicado: (2020)

Timing of Hepatitis C Virus Treatment in Liver Transplant Candidates in the Era of Direct-acting Antiviral Agents
por: Cholankeril, George, et al.
Publicado: (2017)

Interferon Response in Hepatitis C Virus-Infected Hepatocytes: Issues to Consider in the Era of Direct-Acting Antivirals
por: Sung, Pil Soo, et al.
Publicado: (2020)

Predicting Treatment Failure for Initiators of Hepatitis C Virus Treatment in the era of Direct-Acting Antiviral Therapy
por: Nabulsi, Nadia A., et al.
Publicado: (2020)

HCV-Associated Nephropathies in the Era of Direct Acting Antiviral Agents
por: Angeletti, Andrea, et al.
Publicado: (2019)

The ‘Viennese epidemic’ of acute HCV in the era of direct‐acting antivirals
por: Chromy, David, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_csvj5klpua2d1bieib8v68crij